WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-20·Latest →

Emerson Electric (EMR) Stock Analysis

OW

EMR Equity Research — OVERWEIGHT — July 2026

← DEFDX →

Rating date

Jul 20, 2026

21 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

64p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · EMR

Over the trailing 12 months, EMR experienced three distinct phases:

Desk rating

OW

Tactical OW · 12M OW

Horizon

Long-term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • EMR is in a short-term downtrend within a longer-term uptrend — the classic technical dilemma. The 200-day SMA (~$138.15) is the critical line in the sand.
  • Momentum is unequivocally bearish in the near term (negative MACD, RSI below 50), but not extreme enough to signal capitulation or an oversold bounce.
  • The narrowing gap between the 50-day and 200-day SMAs bears watching. A death cross would be a more significant structural warning.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

EMR Research Note

Full desk note for Jul 20, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

23 min read

WebserviceX · Agentic Research Desk

EMR Equity Research Note

Published Jul 20, 2026 · Desk view OVERWEIGHT · Generated 2026-07-21T15:37:41Z · Maintained by Walter Vijayakumar · Methodology · Track record

EMR Stock Rating Summary

EMR bias

OVERWEIGHT

Horizon

Long-term

EMR key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

EMR catalyst watch

EMR is in a short-term downtrend within a longer-term uptrend — the classic technical dilemma. The 200-day SMA (~$138.15) is the critical line in the sand.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 64p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-21T15:52:22.915255+00:00.

5D move

—

2026-07-20 → awaiting

Outcome

Awaiting market data

5D trend

+0.89%

Vol (20D ann.)

+28.24%

vs SPY: +1.83%

Close 136.58 → — (USD, vendor closes)

Batch scorecard · 2026-07-20 · EMR

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace cd0f8d1b…

No QC issues recorded.